{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:58:19Z","timestamp":1761865099064,"version":"build-2065373602"},"reference-count":12,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,12]]},"abstract":"\n The efficacy and safety of once\u2010weekly dulaglutide 0.75\u2009mg (dulaglutide) in\n J<\/jats:styled-content>\n apanese patients with type 2 diabetes (\n T2D<\/jats:styled-content>\n ) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This exploratory analysis included data from a randomized, open\u2010label, phase\n III<\/jats:styled-content>\n study that compared dulaglutide with insulin glargine (glargine) (n\u2009=\u2009361). The three subgroups were dulaglutide or glargine in combination with sulphonylurea (\n SU<\/jats:styled-content>\n ) alone, biguanide (\n BG<\/jats:styled-content>\n ) alone or\n SU<\/jats:styled-content>\n and\n BG<\/jats:styled-content>\n combined. There were no clinically relevant differences in glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ) changes among the three subgroups in the dulaglutide group; in the glargine group, a numerically greater reduction was observed in combination with\n BG<\/jats:styled-content>\n alone compared to the other two groups (\n SU<\/jats:styled-content>\n alone and\n SU<\/jats:styled-content>\n \u2009+\u2009\n BG<\/jats:styled-content>\n ). Weight loss was observed with dulaglutide in combination with\n BG<\/jats:styled-content>\n alone or with\n SU<\/jats:styled-content>\n \u2009+\u2009\n BG<\/jats:styled-content>\n . The incidence of adverse events among subgroups was significantly different in the glargine group but not in the dulaglutide group. Incidence of hypoglycaemia was highest in combination with\n SU<\/jats:styled-content>\n for both treatments. For patients with\n T2D<\/jats:styled-content>\n , dulaglutide added to concomitant\n BG<\/jats:styled-content>\n may be more likely to result in weight loss than dulaglutide added to concomitant\n SU<\/jats:styled-content>\n .\n <\/jats:p>","DOI":"10.1111\/dom.12758","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T23:36:46Z","timestamp":1470267406000},"page":"1279-1282","source":"Crossref","is-referenced-by-count":7,"title":["The combination of dulaglutide and biguanide reduced bodyweight in\n J<\/scp>\n apanese patients with type 2 diabetes"],"prefix":"10.1111","volume":"18","author":[{"given":"Nobuya","family":"Inagaki","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition Kyoto University Graduate School of Medicine Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences Kumamoto University Kumamoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Oura","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Matsui","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, Hematological Science and Therapeutics Yamaguchi University Graduate School of Medicine Yamaguchi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1080"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12534"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12540"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0401"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0518"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_6_9_1","unstructured":"Japan Diabetes Association.Committee on the proper use of incretin drugs (GLP\u20101 receptor agonists and DPP\u20104 inhibitors).2011.http:\/\/www.fa.kyorin.co.jp\/jds\/uploads\/photos\/797.pdf. Accessed June 21 2016 [in Japanese]."},{"key":"e_1_2_6_10_1","unstructured":"Eli Lilly Japan K.K. Trulicity Ateos [Japan package insert].2016.http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/530471_2499416G1029_1_05.pdf. Accessed June 21 2016 [in Japanese]."},{"key":"e_1_2_6_11_1","unstructured":"Eli Lilly and Company. Trulicity [Prescribing information].2015.http:\/\/pi.lilly.com\/us\/trulicity\u2010uspi.pdf. Accessed June 21 2016."},{"key":"e_1_2_6_12_1","unstructured":"Eli Lilly and Company. Trulicity [Summary of product characteristics]2015.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002825\/WC500179470.pdf. Accessed June 21 2016."},{"key":"e_1_2_6_13_1","first-page":"531","volume-title":"Ellenberg & Rifkin's Diabetes Mellitus","author":"Mudaliar S","year":"2003"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12758","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:53:42Z","timestamp":1761864822000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/dom.12758"],"URL":"https:\/\/doi.org\/10.1111\/dom.12758","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}